Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Budesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 0.98 |
| ▸ | PGR | P06401 | 7/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | IL5 | P05113 | 1/20 | 0.98 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.98 |
| ▸ | AR | P10275 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | MMP9 | P14780 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | THPO | P40225 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexbudesonide SCHEMBL868335 | 1.00 | NR3C1 (0.98) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17168987 | 0.99 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17971368 | 0.99 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL12440030 | 0.99 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13918824 | 0.99 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17151422 | 0.99 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL10020756 | 0.99 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL19635 | 0.99 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL21570019 | 0.99 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL9763339 | 0.99 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510570-A | Budesonide-21-succinic acid ester (I) or pharmaceutically acceptable salt and application thereof | 天津普汇科技咨询有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-117510570-A | Budesonide-21-succinic acid ester (I) or pharmaceutically acceptable salt and application thereof | 天津普汇科技咨询有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-10064877-B2 | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress | THERAPEUTIC RESEARCH, LLC (US) | 2018-09-04 | — | — | US | disclosed |
| US-20170296559-A1 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | THERAPEUTIC RES LLC (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170182067-A1 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | THERAPEUTIC RES LLC (US) | 2017-06-29 | — | — | US | disclosed |
| US-9511049-B2 | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress | THERAPEUTIC RESEARCH LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150105356-A1 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | THERAPEUTIC RESEARCH LLC (US) | 2015-04-16 | — | — | US | disclosed |
| US-8916546-B2 | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress | THERAPEUTIC RESEARCH LLC (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130344184-A1 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | THERAPEUTIC RESEARCH LLC (US) | 2013-12-26 | — | — | US | disclosed |
| US-8476233-B2 | Methods for treatment for ulcerative colitis in mammals | THERAPEUTIC RESEARCH, LLC (US) | 2013-07-02 | — | — | US | disclosed |
| CN-101707877-B | Materials and methods for diagnosis and treatment of oxidative stress disorders | PRAVDA JAY | 2013-01-09 | — | — | CN | disclosed |
| US-20120077783-A1 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | THERAPEUTIC RESEARCH LLC (US) | 2012-03-29 | — | — | US | disclosed |
| EP-2392321-A1 | Combined composition for rectal administration for the treatment of inflammatory bowel disease | Pravda, Jay (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2162125-B1 | Composition for rectal administration combined with an oral alpha-lipoic acid composition for the treatment of inflammatory bowel disease | PRAVDA JAY (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100184728-A1 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | THERAPEUTIC RESEARCH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| CN-101707877-A | Materials and methods for diagnosis and treatment of oxidative stress disorders | JAY PRAVDA | 2010-05-12 | — | — | CN | disclosed |
| EP-2162125-A2 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | Pravda, Jay (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008156671-A2 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | PRAVDA JAY (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10064877-B2 | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress | NR3C1, GSTA1, LTC4S | NR3C1 1/4885PGR 3223/4885CYP3A4 1978/4885 |
| US-20100184728-A1 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | NR3C1, GSTA1, LTC4S | NR3C1 1/4885PGR 3223/4885CYP3A4 1978/4885 |
| US-20170296559-A1 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | NR3C1, GSTA1, LTC4S | NR3C1 1/4885PGR 3223/4885CYP3A4 1978/4885 |
| US-20150105356-A1 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | NR3C1, GSTA1, LTC4S | NR3C1 1/4885PGR 3223/4885CYP3A4 1978/4885 |
| US-20120077783-A1 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | TNF, LPO, MPO | NR3C1 1059/4885PGR 3552/4885CYP3A4 2054/4885 |
| US-20170182067-A1 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | NR3C1, GSTA1, LTC4S | NR3C1 1/4885PGR 3223/4885CYP3A4 1978/4885 |
| US-20130344184-A1 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS | MPO, TNF, LPO | NR3C1 842/4885PGR 3433/4885CYP3A4 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.